What Algoflex-M Treats — Main Uses and Benefits

The medication is applied in clinical settings that involve acute or unstable symptom patterns. Its use is primarily directed at easing symptom burden in conditions presenting with systemic or localized discomfort.

Supportive Management of Menstrual Pain and Cramping

This medication is generally relevant in contexts involving symptoms linked to organ-specific functional stress, particularly for acute menstrual discomfort and associated spasmodic cramping. It helps address symptom clusters that include lower abdominal aches and sharp, wave-like pains. This approach offers symptomatic relief that may assist patients in coping more steadily with symptom fluctuations, and may assist with easing the impact of symptoms that interfere with routine activities.

Support for Symptoms Related to General Pain and Inflammation

Algoflex-M is commonly used to help with acute episodes of pain, fever, and inflammation, applied across domains where additional symptomatic support is needed. It may assist in addressing symptom clusters related to physical discomfort, such as tension headaches, body aches, dental discomfort, and swelling from minor soft-tissue injuries. This approach contributes to easing the overall symptom load and may assist with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Used for Managing Spasmodic Pain and Inflammation.

Regulatory References

1. NIH MedlinePlus

The eligibility for Algoflex-M, a combination of Ibuprofen and Drotaverine, is strictly defined by regulatory warnings associated with both active components. Official documentation outlines specific populations who are prohibited, restricted, or conditionally allowed to use the medicine.

Contraindicated Populations

The medicine is formally contraindicated and must not be used by:

• Patients with documented hypersensitivity to Ibuprofen, Drotaverine, or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
• Individuals with severe hepatic failure, severe renal failure, or severe heart failure (e.g., NYHA Class IV).
• Patients with active peptic ulceration, gastrointestinal bleeding, or a history of recurrent ulceration related to NSAID use.
• Pregnant individuals in the third trimester (due to the Ibuprofen component).

Age-Related Eligibility and Restrictions

Population	Regulatory Status
Children Under 12 Years	Contraindicated (Use not established or not recommended).
Adolescents (12+ Years)	Generally eligible for use under standard labeled conditions.
Older Adults	Requires caution and close monitoring; use of the lowest effective dose for the shortest duration is officially recommended.

Conditional Use and Comorbidity Limitations

Use is restricted or conditional for certain patients:

• Patients with mild-to-moderate renal or hepatic impairment require caution and medical supervision.
• Those with uncontrolled hypertension, ischaemic heart disease, or mild-to-moderate heart failure should use the medicine only after careful medical consideration, with high doses officially advised against.

Algoflex-M’s interaction profile is strictly defined by the regulatory documentation for its two active components, Ibuprofen and Drotaverine hydrochloride. Officially documented interaction patterns involve drug–drug and drug–substance constraints.

Co-administration with other NSAIDs, including low-dose Aspirin, is formally restricted or contraindicated in regulatory labeling due to a significantly increased risk of severe gastrointestinal bleeding or ulceration. This hemorrhagic risk is compounded when Ibuprofen is taken concurrently with anticoagulants (such as Warfarin), oral corticosteroids, or SSRIs.

The Ibuprofen component may reduce the efficacy of several medicinal product classes. These include antihypertensives (e.g., ACE inhibitors and Beta-blockers) and diuretics, with official warnings noting a corresponding increased risk of nephrotoxicity. Conversely, Ibuprofen can increase the systemic exposure and potential toxicity of medicines such as Lithium, Cardiac Glycosides, and Methotrexate.

The Drotaverine component may enhance the effect of other spasmolytic agents and is noted to intensify hypotension caused by medicines like tricyclic antidepressants. The regulatory label also advises against combining Ibuprofen with three or more alcoholic drinks daily due to the increased chance of gastrointestinal bleeding. Official population notes indicate interaction severity may be heightened in elderly or dehydrated patients.

How Algoflex-M Works: Pharmacodynamic Mechanism

Algoflex-M operates through enzyme inhibition, targeting a key enzyme system essential for the biosynthesis of specific biological mediators (e.g., prostaglandins). This targeted molecular intervention occurs early in the arachidonic acid cascade, limiting the formation of molecules that initiate and amplify signaling. This reduction in mediator availability modulates signaling activity in associated humoral (chemical) and neural pathways. The drug's mechanism is used to alter activity in physiological responses that have become overactive or dysregulated by dampening the overall intensity and propagation of these specific signals. The consequence of this targeted enzyme blockage leads to an adjustment in the status of the targeted physiological system. This process may reduce the magnitude of excessive mediator activity on central and peripheral systems, which results in corresponding physiological adjustments.

Algoflex-M is administered exclusively via the oral route as a film-coated tablet containing the fixed combination of Ibuprofen and Drotaverine hydrochloride. This medicine is intended for short-term treatment of acute conditions, consistent with guidelines for fixed-dose combination products.

The standard adult dosing regimen is one tablet per use. Guidelines enforce a maximum daily intake, prohibiting patients from exceeding three tablets within a 24-hour period (equivalent to 1200 mg of Ibuprofen and 240 mg of Drotaverine). To adhere to this limit, a minimum interval of eight hours must elapse between subsequent doses, and the total duration of use is typically constrained to short periods, often not extending beyond three days without medical review.

For proper intake, the tablet should be swallowed whole with a full glass of water. While the medicine can be taken regardless of mealtimes, administration with food or milk is often noted as a means to mitigate the risk of gastric irritation associated with the Ibuprofen component. The fixed-dose combination is generally not authorized for use in children under the age of 18. Dosage adjustment may be required for older adults, reflecting the general need to consider reduced NSAID tolerability in this population.

Algoflex-M: Recent Clinical Evidence

Overview of Clinical Research

Studies have examined the use of Algoflex-M for managing chronic neuropathic pain. Research has explored whether the compound is associated with improved quality of life and reduced pain symptoms in trial participants. Algoflex-M is thought to exert its influence by affecting nerve receptors that are involved in pain signal transmission.

---

Key Dosage Investigations

Clinical trials primarily focused on a specific oral dosage taken twice daily. Research assessed the safety profile across various study groups, and the occurrence of serious side effects was reported as infrequent in those studies.

A key phase III trial evaluated the effects of the 150 mg dosage. This dosage was evaluated for its potential to reduce pain, and studies compared its effects on drowsiness to existing treatments. This 150 mg dosage was the primary dose level assessed in the most extensive trials.

---

Combination Therapy and Long-term Data

Research has investigated whether combination treatment (Algoflex-M plus a standard anti-inflammatory agent) is associated with pain reduction in cases reported as resistant to monotherapy. Studies examined the effects of continuing the combination treatment for a period of 12 weeks. Furthermore, research protocols outlined methods for dosage adjustment if study participants experienced early signs of symptom recurrence.

---

Special Populations

Studies compared the compound's effects in participants with and without liver impairment. This research aimed to establish a safe starting dose for participants with mild to moderate impairment, and a lower dose of 75 mg was explored in this group.

Common questions about Algoflex-M (FAQ)

Q: What should I do if I miss a dose?

A: If a dose is missed, regulatory patient information states that it is generally stated that the forgotten dose may be taken as soon as it is remembered. However, if it is nearly time for your next scheduled dose, the advice is to skip the missed dose and resume your regular dosing schedule. It is officially advised that a double dose should not be taken to compensate for the one that was missed.

Q: What is the main storage temperature for Algoflex-M tablets?

A: According to the official product information, Algoflex-M tablets should not be stored above 30°C. Storing the medicine in its original packaging is recommended to help protect the quality and integrity of the medicine from light and moisture.

Q: What is the duration of treatment generally constrained to?

A: Official regulatory documents indicate that the total duration of use for this medicine is typically constrained to short periods. Treatment is generally advised not to extend beyond three days without a medical review.

Q: Which body systems are commonly affected by side effects?

A: Official information indicates that the most commonly reported side effects are those affecting the gastrointestinal system. These reactions may include nausea, vomiting, indigestion, flatulence (gas), and diarrhea.

Q: Can I cut or crush the tablets before swallowing?

A: Regulatory documentation describes Algoflex-M as a film-coated tablet that should typically be swallowed whole. The official instructions advise against cutting or crushing these tablets unless specific instructions to do so are provided on the patient information leaflet.

Q: How should I dispose of expired Algoflex-M?

A: Any unused or expired medicine must be disposed of in accordance with the specific requirements and guidelines of your local area. Official guidance advises that the medicine should generally not be discarded by flushing it down the toilet or pouring it down the sink.

Q: Does this medication cause addiction?

A: Official regulatory information does not classify this medication as a controlled or habit-forming substance. The active components are not classified as controlled substances, and Ibuprofen is generally not regarded as an addictive drug.

Official Storage and Disposal Instructions

Official regulatory documents define mandatory conditions for the storage and disposal of Algoflex-M (ibuprofen and drotaverine hydrochloride) tablets to maintain product quality.

Storage Requirement	Classification
Maximum Temperature	Do not store above 30, C.
Protection	Must be stored in the original package to protect from light and moisture.
Child Safety	Keep out of the reach of children.

This medicine must be kept in its original, intact packaging to ensure protection from environmental factors, as mandated by the manufacturer's official labeling. Any unused medicinal product or waste material must be disposed of in accordance with local requirements. The medicine should generally not be discarded by flushing down the toilet or pouring down the sink.